Vyant Bio

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded in 1999 and is headquartered in Cherry Hill, NJ.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will release its financial results for the second quarter and first half ended June 30, 2022, on Monday, August 15, 2022. Vyant Bio will host an investor conference call and webcast on Monday, August 15, 2022 at 4:30 pm ET.

Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022

Cherry Hill, New Jersey--(Newsfile Corp. - August 3, 2022) - Vyant Bio, Inc. (NASDAQ: VYNT) ("Vyant Bio" or "Company") is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will be participating in the Q3 Virtual Investor Summit.

Vyant Bio to Present at Investor Summit Group's Q3 Virtual Conference

CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it has retained the services of Skyline Corporate Communications Group, LLC (“Skyline”) to manage its investor relations and corporate communications activities within the financial community.

Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services

Vyant Bio, Inc. (NASDAQ:VYNT ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Robert Fremeau - Chief Scientific Officer Conference Call Participants Ed White - H.C. Wainwright Michael Mortensen - WestPark Capital Operator Good afternoon, and welcome to the Vyant Bio First Quarter 2022 Earnings Conference Call and Webcast.

Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q1 2022 Results - Earnings Call Transcript

Vyant Bio (NASDAQ:VYNT) Inc ended its first quarter with $16.4 million after a busy three months that saw it progress the discovery of small molecule therapeutics to treat neurological diseases. In the period to March 31, 2022, the Cherry Hill, New Jersey-based company implemented an up to $14.5 million at the market financing vehicle with Canaccord Genuity (TSX:CF, LSE:CF) and another equity line of credit facility with Lincoln Park Capital for up to $15 million.

Vyant Bio ends 1Q with $16.4M in cash to fund small molecule therapeutics research for neurological diseases

Conference Call and Webcast Today at 4:30 pm ET

Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights

CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Monday, May 16, 2022.

Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022

CHERRY HILL, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders, announced that Jay Roberts, Chief Executive Officer, will present at BioNJ's 12th Annual BioPartnering Conference. One-on-one partnering meetings will be held throughout the week (May 9-13, 2022). An on-demand replay of Vyant Bio's presentation will be available to registered guests.

Vyant Bio Announces Participation in BioNJ's 12th Annual BioPartnering Conference

Adagio Therapeutics

Direct Digital Holdings

Geron

NanoVibronix

Sonoma Pharmaceuticals

Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q4 2021 Results - Earnings Call Transcript

Vyant Bio (NASDAQ:VYNT) Inc ended its 2021 financial year with a beefed-up cash balance of $20.6 million to help the biotechnology company pursue its development of drugs for complex neurodevelopmental and neurodegenerative disorders. The company is focused primarily on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome, CDKL5 Deficiency Disorder, and familial Parkinson's Disease.

Vyant Bio ends 2021 with $20.6M in cash as it sharpens focus on novel drug discovery

Here's what you need to know about trading penny stocks on March 30th The post Trading Penny Stocks? Top Stock Market News for March 30th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 30th, 2022

Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business Highlights

Vyant Bio (NASDAQ:VYNT) Inc said it has entered into a collaboration agreement with OrganoTherapeutics to accelerate the discovery of drugs to treat Parkinson's Disease (PD). The collaboration brings together the companies' expertise in drug discovery using human-derived cells, high-throughput biology and chemistry, and machine learning-based therapeutic design to identify potential drugs to treat PD.

Vyant Bio enters collaboration with OrganoTherapeutics to find treatments for Parkinson's Disease

Vyant Bio Inc (NASDAQ: VYNT) and OrganoTherapeutics have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson's Disease. Specific deal terms were not disclosed.

Vyant Bio Shares Jump On Parkinson's Disease Agreement

Cherry Hill, N.J. and Esch-sur-Alzette, Luxembourg, March 29, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders and OrganoTherapeutics, a developer of proprietary patient-specific organoids that recapitulate Parkinson's Disease (PD) pathology, announced today they have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson's Disease.

Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson's Disease

CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Wednesday, March 30, 2022.

Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021

Vyant Bio (NASDAQ:VYNT) Inc CEO Jay Roberts told shareholders that after its merger the company is “well-positioned” to pursue the discovery of novel therapeutics to treat neurological diseases such as Rett Syndrome, CDKL5 Deficiency Disorders (CDD), and Parkinson's Disease, a progressive nervous system (CNS) disorder that affects movement. The StemoniX and Cancer Genetics merger was completed in early 2021, and Vyant Bio (NASDAQ:VYNT) was created to use its human cell-based microBrain and computer modeling platform, AnalytiX, to identify compounds that target neurological disorders.

Vyant Bio says it is ‘well-positioned' to discover novel therapeutics to treat neurological diseases

Cherry Hill, NJ, March 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics. Today Vyant Bio released a Letter to Shareholders from Chief Executive Officer, Jay Roberts. The complete letter follows.

Vyant Bio Issues Letter to Shareholders

Cherry Hill, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that it will be participating in The Benchmark Company Discovery One-on-One Investor Conference. The event is being held virtually on Thursday, December 2, 2021.

Vyant Bio to Present at The Benchmark Company Discovery One-on-One Investor Conference

Vyant Bio's (VYNT) CEO Jay Roberts on Q3 2021 Results - Earnings Call Transcript

Vyant Bio (NASDAQ:VYNT) Inc announced its third-quarter 2021 strategic and business updates, reporting total revenue of $1.5 million for the three months ending September 30, 2021, compared to $1.9 million in 3Q 2021.  During the quarter, the New Jersey-based company announced that it appointed Robert Fremeau as the new chief scientific officer, who will be lead Vyant Bio (NASDAQ:VYNT)'s research and development programs.

Vyant Bio reports total revenue of $1.5M in 3Q 2021, shares strategic updates

Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates

Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that it will be presenting at the Q4 Investor Summit Micro & Small Cap Conference (“Q4 Investor Summit”). The event is being held virtually from November 16-17, 2021.

Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference

CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio , Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Thursday, November 11, 2021.

News for Vyant Bio Stock (VYNT)